2022 in review: FDA approvals of new medicines.
Drug Discov Today
; 28(8): 103622, 2023 08.
Article
en En
| MEDLINE
| ID: mdl-37201782
ABSTRACT
An accounting of all new entities approved by both the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER) identified the approval of 44 new entities in the year 2022. Oncology-based drugs continued to be the most popular indication for these medicines. Likewise, orphan indications encompassed more than half of new drug approvals. The number of new entities approved in 2022 declined from its peak after 5 years of more than 50 annual approvals. Likewise, the rate of consolidations slowed somewhat, among both new entries in the realm of clinical-stage developers and more established organizations.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Aprobación de Drogas
País como asunto:
America do norte
Idioma:
En
Año:
2023
Tipo del documento:
Article